冻干水痘减毒活疫苗最小免疫剂量的研究

通过临床研究确定冻干水痘减毒活疫苗的最小免疫剂量 ,为制定规程中的免疫剂量提供科学依据。观察对象接种不同免疫剂量的冻干水痘减毒活疫苗后 ,于接种前和接种后 6周采血 ,采用荧光抗膜抗体 (FAMA)法检测其抗体阳转率和几何平均滴度 (GMT)。接种不同免疫剂量的疫苗 ,抗体阳转率差异无显著的统计学意义。疫苗中抗原含量在 2 5 0 0 0PFU/ml和 2 0 0 0PFU/ml之间 ,GMT差异无显著的统计学意义 ,但 2 5 0 0 0PFU/ml、2 0 0 0PFU/ml与 2 0 0PFU/ml之间抗体GMT的差异有极显著的统计学意义。研究结果表明 ,2 0 0 0PFU/ml为冻干水痘减毒活疫苗的最小免疫剂量。     

In vivo and in vitro anti-tumour response of selenium-protein polysaccharide extracted from rich selenium Agaricus blazei

In this study, the anti-tumour activity of selenium-protein polysaccharide (SPP), a water extract of the rich selenium Agaricus blazei, was tested both in vivo and in vitro. The results of in vivo experiments show that SPP at doses of 50 and 100 mg/kg inhibits proliferation of implanted Sarcoma 180 by 22 and 37.69%, respectively, and promotes lymphocyte transformation and natural killer (NK) cells activity in tumour bearing mice. During the in vitro experiment, we treated the tumour and non-tumour bearing mice with SPP, and prepared serum treated with SPP (Serum_SPP). The results show that Serum_SPP, whether from tumour or non-tumour bearing mice, significantly inhibits K562 cells proliferation and induces their apoptosis, and also significantly increases caspase-3 activity of K562 cells. However, the difference in anti-tumour activity of Serum_SPP between tumour and non-tumour bearing mice is significantly different (p<0.01). The results, according to the studies both in vivo and in vitro, imply that SPP extracted from rich selenium A. blazei can inhibit growth of implanted Sarcoma 180 and promote lymphocyte transformation and NK cells activity in vivo. Additionally, Serum_SPP can inhibit proliferation and cause apoptotic morphological changes and the fragmentation of internucleosomal DNA, and increase caspase-3 activity of K562 cells in vitro, which indicates that apoptosis of K562 cells induced by Serum_SPP may be related to up-regulation of caspase-3.     

Protective effectiveness of an endotoxin-depleted pertussis vaccine

Pertussis vaccine depleted of endotoxin by the polymyxin-Sepharose affinity chromatography method was tested for toxic activity and protective effectiveness in mice. Preparations containing 1000-fold and 1 000 O00-fold less endotoxin fulfilled the established experimental criteria for freedom from toxicity. A fourfold concentrate of the former demonstrated a protection rate only 10% less than that of standard, untreated pertussis vaccine.     

枸杞多糖对运动性骨骼肌疲劳恢复的细胞定量化学分析和电镜观察

通过小鼠实验，用枸杞多糖解除运动性骨骼肌疲劳，以显微分光光度计进行琥珀酸脱氢酶(SDH)和糖原的定性定量分析，并于透射电镜下观察超微结构的变化。结果显示，运动疲劳(B)组糖原含量明显降低，各类肌纤维与对照(A)组比较P<0．001。SDH活性增加，各类肌纤维与A组比较P<0．001。服用枸杞多糖(C)组糖原含量增加，各类肌纤维与A组之较P<0．001；与B组比较P<0．001；SDH反应较B组更深，各类肌纤维与A组比较P<0．001，若与B组比较，则其中Ⅰ(慢肌)型和Ⅱ(中间肌)型P<0．001，而Ⅱ(快肌)型则P>0．05。超微结构显示，B组线粒体增多且体积明显增大，呈肿胀状态，C组全无此类改变，提示服用枸杞多糖后可解除疲劳，其中以Ⅰ(慢肌)型肌纤维效果尤佳。     

孩尔来福甲型肝炎灭活疫苗免疫儿童后近期抗体动态观察

为观察孩尔来福 (Healive)甲型肝炎 (甲肝 )灭活疫苗免疫儿童后的抗体水平及下降规律 ,探讨甲肝灭活疫苗诱导的抗体所提供的持续保护时间 ,对曾接种 5 0 0U/剂 (0、3个月和 0、6个月免疫程序 )Healive甲肝灭活疫苗的113名儿童 ,用酶联免疫吸附试验 (ELISA)分别检测免疫后 12、2 4、36个月的血清抗甲肝病毒抗体。结果显示 :至第 36个月检测时 ,10 0 %的儿童甲肝抗体保持阳性 ;0、3个月程序组 74 1% ,0、6个月程序组 85 4 %的儿童甲肝抗体滴度≥ 2 0 0mIU/ml。     

水痘疫苗接种的成本效益

水痘是一种常见的急性、高传染性的疾病 ,可感染儿童、成人。 1974年日本首先研制成功Oka株水痘减毒活疫苗 ,1984年世界卫生组织批准水痘减毒活疫苗用于婴幼儿预防接种 ,许多国家陆续开展了水痘疫苗预防接种 ,不仅能取得良好的防病效果 ,而且可较大地减轻疾病负担。对儿童、青少年、成人、育龄期妇女和免疫功能抑制患者分别进行的经济学评价表明 ,接种水痘疫苗具有较好的成本效益结果。     

新生儿重组酵母乙肝疫苗接种免疫的研究

目的：探讨重组酵母乙肝疫苗新生儿接种后抗体应答持续时间，强化复种的必要性。方法：常规对新生儿0d(出生后当天)、1月、6月接种重组酵母乙肝疫苗后检测抗体应答情况，再随机分两组，一组为强化组，一组为常规组，并随访其5年的抗体应答情况。结果：新生儿常规接种法，于12个月后有一明显抗体应答下降期(0d、1月、6月、12月)，强化组乙肝表面抗体形成率高，持续时间均高于常规接种法。结论：新生儿乙肝疫苗0d、1月、6月、12月接种法有较好的远期保护效果，对现有的0d、1月、6月新生儿乙肝疫苗常规接种法，有强化接种的必要。     

Licensing and control authority batch release of influenza vaccine in Germany in accordance with EEC regulations

The epidemiological situation calls for almost yearly changes in the antigenic composition of influenza vaccine, thus necessitating fresh licensing procedures. Since the time for bringing a new vaccine onto the market should be relatively short, the following work of all parties involved must be done expeditiously: 1) WHO recommendations on new virus strains and their subsequent adaptation by the EEC (February/March); 2) Distribution of the new virus strains to the International Reference Centers for Influenza in the UK and USA (February/ March); the centers later issue reference materials for the determination of the haemagglutinin antigen concentration (April/May); 3) Production and testing of seed virus by manufacturers, as well as validation of the producer's inactivation process for the new virus strains (May/June); 4) Licensing of the vaccines by the National Control Authority (Paul-Ehrlich-Institute) (June/July); in the case of previously licensed products, the procedure is limited essentially to the approval of the detailed protocol of production and tests on the new virus strains, clinical studies not being required before licensing because of a lack of time; 5) Paul-Ehrlich-Institute's test for batch release, according to Directive 89/342/EEC, besides protocol approval, conducts material testing of the endotoxin and antigen content of each vaccine lot; the assay for the antigen quantification is especially laborious and sometimes must be repeated because of test invalidity.     

恶性疟P190抗原保守区Ⅰ、Ⅴ基因的亚克隆及在大肠杆菌中高效表达

作者采用PCR方法克隆了我国海南省FCC1/HN株P190抗原两个保守区基因,分别定名为P190CRI和P190CRV。基因片段经纯化后连接到pUC18载体中进行DNA序列分析,结果显示:除了P190CRV中有5个碱基变换外,其余序列均与MAD20型序列一致。经序列分析的两个基因片段分别与pGEX-2T载体连接,经双酶切鉴定后转化感受态JM109(DE_3)大肠杆菌进行高效融合表达,并且用Sepharose 4B-谷胱甘肽层析柱进行亲和纯化,结果为:两个插入基因片段均得到高效融合表达,经一步亲和纯化后就取得高纯度的重组蛋白。